<p><strong>PALO ALTO</strong> &#8212; <b>Atropos Health</b>, apioneer in translating real-world clinical data into high-quality personalized real-world evidence for care, has landed a $33 million Series B on the heels of the adoption of its Generative AI platform (GENEVA OS) by healthcare institutions, data platforms, research institutions, life sciences companies and more. The funding was led by Valtruis, with participation from new strategic investors including Cencora Ventures, McKesson Ventures, and Merck Global Health Innovation Fund, along with existing investors Breyer Capital, Emerson Collective, and Presidio Ventures.</p>
<p>Atropos Health was founded in 2019 by Brigham Hyde Ph.D., Nigam Shah MBBS, Ph.D., and Saurabh Gombar M.D., Ph.D., originally developed as the “<a href="https://cts.businesswire.com/ct/CT?id=smartlink&;url=https%3A%2F%2Fwww.youtube.com%2Fwatch%3Fv%3Dw9Jm04ZxPLw&;esheet=54014501&;newsitemid=20240523484154&;lan=en-US&;anchor=Green+Button&;index=1&;md5=73ef82a65119102ec4e4016f77ac9c42" target="_blank" rel="nofollow noopener" shape="rect">Green Button</a>” project at Stanford University. The trio are leaders in applications of AI and real-world evidence research in healthcare, and on a mission to democratize access to high-quality real-world evidence (RWE) as a means to improve decision making and outcomes in healthcare. Since then, the company has emerged as a leader in the application of generative AI thanks to unique vertical user experiences like ChatRWD™ which reduces the time to produce high-quality publication-grade real-world evidence from months to minutes through a chat-based AI co-pilot.</p>
<p>“As excitement over the application of Generative AI technology in healthcare turns from potential to practical applications, the focus of providers, life sciences, and other healthcare stakeholders turns to quality, transparency, and automation backed by tangible ROI. For decades, high-quality clinical evidence has served as the currency of value in healthcare. Atropos Health is built on investment in scaling the production of high-quality, transparent, and now real-time evidence production that matches the standards of the clinical and research communities,” said Brigham Hyde, CEO and Co-Founder of Atropos Health. “This funding round, which includes multiple major strategic stakeholders in the healthcare ecosystem, is validation that our platform is rapidly becoming the standard not only for automation and user experience, but also as the trusted quality layer between healthcare data and the critical evidence needed to better inform patient care, research, and policy.”</p>
<p><b>Investing in Real-World Evidence for Value-Based Care Decision-Making</b></p>
<p>With this funding, Atropos Health plans to further its stake in value-based care. The company’s portfolio of evidence-generating applications supports whole-person care and value-based performance and has long been utilized by Atropos Health partners including Arcadia. Through Atropos Health, healthcare organizations are able to accelerate appropriate clinical decision-making to drive high-value, low-cost care for patients based on their unique physiology. To drive this mission further, Atropos Health is welcoming value-based care veteran Mike Spadafore to its board.</p>
<p>“For nearly 15 years, I’ve had a front-row seat to value-based care&#8217;s evolution and positive impact on patients, physicians, and communities. I am excited about Atropos Health and its ability to automate personalized, real-world evidence at scale for both providers and researchers,” said Spadafore, Managing Director of Valtruis. “Atropos Health has the potential to dramatically improve existing workflows across both life sciences and health systems, in turn improving clinician decision-making and driving better outcomes for patients. We are thrilled to partner with Atropos in this journey.”</p>
<p><b>Expanding the Atropos Evidence™ Network Including Vertical Integrations with Oncology and Specialty areas</b></p>
<p>As a part of this round, Atropos Health will enter into strategic relationships with partners from life sciences and vertically integrated healthcare players. Through Cencora, a leading global pharmaceutical solutions organization, Atropos Health will bring its real-world evidence platform to oncology and specialty care. Evidence for care is critical in the rapidly evolving treatment landscape for oncology, where the stakes are high for cancer patients. Now, oncologists and researchers can leverage the Atropos Evidence Network of millions of anonymized patient data converted to high-quality evidence to inform their decision-making process. In turn, pharmaceutical customers of Atropos Health, such as <a href="https://cts.businesswire.com/ct/CT?id=smartlink&;url=https%3A%2F%2Fwww.atroposhealth.com%2Fblog%2Fatropos-health-announces-agreement-to-accelerate-real-world-evidence-generation-nbsp&;esheet=54014501&;newsitemid=20240523484154&;lan=en-US&;anchor=Janssen+Research+%26amp%3B+Development%2C+LLC+%28Janssen%29%2C+a+Johnson+%26amp%3B+Johnson+company&;index=2&;md5=b2d0d4c978b763e33c2c08b364788813" target="_blank" rel="nofollow noopener" shape="rect">Janssen Research &; Development, LLC (Janssen), a Johnson &; Johnson company</a>, can leverage this evidence network to drive critical R&;D initiatives and accelerate the time of the development of the next treatment.</p>
<p>“Atropos Health addresses a very real problem that both health systems and pharmaceutical manufacturers face in turning medical data into insights in a timely, predictable, and cost-effective manner.” said Michelle Snyder, Partner at McKesson Ventures. “As leading industry players increasingly recognize the value of having the right data, rather than just having the most data, Atropos Health stands out in its ability to understand and score datasets in a compliant and secure manner in order to accelerate research and improve patient outcomes.”</p>

MOUNTAIN VIEW -- ALM Ventures has announced the launch of ALM Ventures Fund I, a…
SAN FRANCISCO -- Brainworks Ventures, an AI-native venture capital fund led by DARPA alumnus Dr.…
OpenAI is hiring Slack CEO Denise Dresser as the company's Chief Revenue Officer, overseeing global…
The Santa Clara County District Attorney’s Office has charged a San Jose 17-year-old with attempted…
SANTA CLARA — Lemurian Labs has secured $28 million in an oversubscribed Series A round,…
EMERYVILLE -- Ripple Foods, a producer of high-protein, allergen-free plant-based milks, has landed $17 million in…